Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

3rd World Bronchiectasis Conference.

O'Donnell AE, Aksamit TR.

Chronic Obstr Pulm Dis. 2018 Oct 2;5(4):302-323. doi: 10.15326/jcopdf.5.4.2018.0132. No abstract available.

2.

Bronchiectasis and Chronic Airway Disease: It Is Not Just About Asthma and COPD.

Martinez-Garcia MA, Polverino E, Aksamit T.

Chest. 2018 Oct;154(4):737-739. doi: 10.1016/j.chest.2018.02.024. No abstract available.

PMID:
30290922
3.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Sep 14. doi: 10.1164/rccm.201807-1318OC. [Epub ahead of print]

PMID:
30216086
4.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

5.

Mycobacterium avium Complex and Bronchiectasis. There's Something Happening Here . . .

Griffith DE, Aksamit TR.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1252-1253. doi: 10.1164/rccm.201807-1243ED. No abstract available.

PMID:
30092144
6.

Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.

Henkle E, Chan B, Curtis JR, Aksamit TR, Daley CL, Winthrop KL.

Chest. 2018 Dec;154(6):1311-1320. doi: 10.1016/j.chest.2018.07.014. Epub 2018 Jul 25.

PMID:
30055168
7.

US Patient-Centered Research Priorities and Roadmap for Bronchiectasis.

Henkle E, Aksamit TR, Daley CL, Griffith DE, O'Donnell AE, Quittner AL, Malanga E, Prieto D, Leitman A, Winthrop KL.

Chest. 2018 Nov;154(5):1016-1023. doi: 10.1016/j.chest.2018.06.032. Epub 2018 Jul 5.

PMID:
29981718
8.

Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Theel ES, Hilgart H, Breen-Lyles M, McCoy K, Flury R, Breeher LE, Wilson J, Sia IG, Whitaker JA, Clain J, Aksamit TR, Escalante P.

J Clin Microbiol. 2018 Jun 25;56(7). pii: e00614-18. doi: 10.1128/JCM.00614-18. Print 2018 Jul.

9.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar. No abstract available.

PMID:
29567726
10.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

PMID:
29371384
11.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

PMID:
29371383
12.

The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis.

Metersky ML, Aksamit TR, Barker A, Choate R, Daley CL, Daniels LA, DiMango A, Eden E, Griffith D, Johnson M, Knowles M, O'Donnell AE, Olivier K, Salathe M, Thomashow B, Tino G, Turino G, Winthrop KL, Mannino D.

Ann Am Thorac Soc. 2018 Mar;15(3):365-370. doi: 10.1513/AnnalsATS.201706-426OC.

13.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

14.

Frequency of untreated hypogammaglobulinemia in bronchiectasis.

Ruffner MA, Aksamit TR, Thomashow B, Choate R, DiMango A, Turino GM, O'Donnell AE, Johnson MM, Olivier KN, Fennelly K, Daley CL, Winthrop KL, Metersky ML, Salathe MA, Knowles MR, Daniels MLA, Noone PG, Tino G, Griffith DE, Sullivan KE.

Ann Allergy Asthma Immunol. 2017 Jul;119(1):83-85. doi: 10.1016/j.anai.2017.04.020. Epub 2017 May 20. No abstract available.

PMID:
28539185
15.

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8.

16.

Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, DiMango A, Eden E, Fennelly K, Griffith DE, Johnson M, Knowles MR, Leitman A, Leitman P, Malanga E, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Prieto D, Salathe M, Thomashow B, Tino G, Turino G, Wisclenny S, Winthrop KL.

Chest. 2017 Dec;152(6):1120-1127. doi: 10.1016/j.chest.2017.04.167. Epub 2017 May 5.

17.

Additional important research priorities for bronchiectasis in China.

Aliberti S, Dhar R, Aksamit TR, Morgan L, Chalmers JD.

Eur Respir J. 2017 Jan 18;49(1). pii: 1602317. doi: 10.1183/13993003.02317-2016. Print 2017 Jan. No abstract available.

18.

Understanding nontuberculous mycobacterial lung disease: it's been a long time coming.

Griffith DE, Aksamit TR.

F1000Res. 2016 Nov 30;5:2797. eCollection 2016. Review.

19.

Nontuberculous Mycobacterial Disease Therapy: Take It to the Limit One More Time.

Griffith DE, Aksamit TR.

Chest. 2016 Dec;150(6):1177-1178. doi: 10.1016/j.chest.2016.07.015. No abstract available.

PMID:
27938739
20.

Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Aksamit TR, O'Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, Johnson M, Eden E, Griffith D, Knowles M, Metersky M, Salathe M, Thomashow B, Tino G, Turino G, Carretta B, Daley CL; Bronchiectasis Research Registry Consortium.

Chest. 2017 May;151(5):982-992. doi: 10.1016/j.chest.2016.10.055. Epub 2016 Nov 23.

21.

The EMBARC European Bronchiectasis Registry: protocol for an international observational study.

Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, Murris-Espin M, Masefield S, Gerada E, Shteinberg M, Ringshausen F, Haworth C, Boersma W, Rademacher J, Hill AT, Aksamit T, O'Donnell A, Morgan L, Milenkovic B, Tramma L, Neves J, Menendez R, Paggiaro P, Botnaru V, Skrgat S, Wilson R, Goeminne P, De Soyza A, Welte T, Torres A, Elborn JS, Blasi F.

ERJ Open Res. 2016 Jan 20;2(1). pii: 00081-2015. eCollection 2016 Jan.

22.

Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report.

Henkle E, Aksamit T, Barker A, Daley CL, Griffith D, Leitman P, Leitman A, Malanga E, Marras TK, Olivier KN, Prevots DR, Prieto D, Quittner AL, Skach W, Walsh JW, Winthrop KL; NTMRC Patient Advisory Panel.

Ann Am Thorac Soc. 2016 Sep;13(9):S379-84. doi: 10.1513/AnnalsATS.201605-387WS.

23.

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, Hill AT, Menendez R, Polverino E.

Respir Med. 2016 Aug;117:179-89. doi: 10.1016/j.rmed.2016.06.007. Epub 2016 Jun 7. Review.

24.

Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.

Hamadah AM, Beaulieu LM, Wilson JW, Aksamit TR, Gregoire JR, Williams AW, Dillon JJ, Albright RC, Onuigbo M, Iyer VK, Hickson LJ.

Nephron. 2016;132(3):198-206. doi: 10.1159/000444148. Epub 2016 Feb 10.

25.

Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.

Philley JV, Wallace RJ Jr, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, Aksamit TR, Griffith DE.

Chest. 2015 Aug;148(2):499-506. doi: 10.1378/chest.14-2764.

26.

The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease.

Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR.

Eur Respir J. 2015 Apr;45(4):1177-9. doi: 10.1183/09031936.00169114. Epub 2015 Jan 22. No abstract available.

27.

Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Oct;11(8):1298-306. doi: 10.1513/AnnalsATS.201405-203AS. Review.

28.

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. Review.

29.

Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials.

Aksamit TR, Philley JV, Griffith DE.

Respir Med. 2014 Mar;108(3):417-25. doi: 10.1016/j.rmed.2013.09.014. Epub 2013 Sep 25. Review.

30.

Immunoglobulin G4-related disease mimicking asthma.

Sekiguchi H, Horie R, Aksamit TR, Yi ES, Ryu JH.

Can Respir J. 2013 Mar-Apr;20(2):87-9.

31.

Bronchiectasis and nontuberculous mycobacterial disease.

Griffith DE, Aksamit TR.

Clin Chest Med. 2012 Jun;33(2):283-95. doi: 10.1016/j.ccm.2012.02.002. Epub 2012 Apr 4. Review.

PMID:
22640846
32.

European union standards for tuberculosis care.

Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D.

Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.

33.

Therapy of refractory nontuberculous mycobacterial lung disease.

Griffith DE, Aksamit TR.

Curr Opin Infect Dis. 2012 Apr;25(2):218-27. doi: 10.1097/QCO.0b013e3283511a64. Review.

PMID:
22327466
34.

Bronchoscopy in suspected pulmonary TB with negative induced-sputum smear and MTD(®) Gen-probe testing.

Iyer VN, Joshi AY, Boyce TG, Brutinel MW, Scalcini MC, Wilson JW, McCoy K, Aksamit TR.

Respir Med. 2011 Jul;105(7):1084-90. doi: 10.1016/j.rmed.2011.03.003. Epub 2011 Mar 21.

35.

Preemployment screening for tuberculosis in a large health care setting: comparison of the tuberculin skin test and a whole-blood interferon-γ release assay.

Khoury NZ, Binnicker MJ, Wengenack NL, Aksamit TR, Buchta WG, Molella RG.

J Occup Environ Med. 2011 Mar;53(3):290-3. doi: 10.1097/JOM.0b013e31820c91c5.

PMID:
21346634
36.

An innovative model for tuberculosis control: an academic medical center-public health department partnership.

Varkey P, Harris S, Edmonson L, McCoy K, Aksamit T, Brennan MD.

Minn Med. 2010 Jan;93(1):39-41.

PMID:
20191731
37.

Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients.

Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A.

Chest. 2008 Apr;133(4):969-74. doi: 10.1378/chest.07-1800. Epub 2008 Jan 15.

PMID:
18198255
38.

Effect of 24-hour mandatory versus on-demand critical care specialist presence on quality of care and family and provider satisfaction in the intensive care unit of a teaching hospital.

Gajic O, Afessa B, Hanson AC, Krpata T, Yilmaz M, Mohamed SF, Rabatin JT, Evenson LK, Aksamit TR, Peters SG, Hubmayr RD, Wylam ME.

Crit Care Med. 2008 Jan;36(1):36-44.

PMID:
18007270
39.

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America.

Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. No abstract available. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.

PMID:
17277290
40.

Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.

Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A.

Am J Respir Crit Care Med. 2006 Jun 1;173(11):1283-9. Epub 2006 Mar 2.

PMID:
16514112
41.

33-year-old woman with pleuritic chest pain and nonproductive cough.

Kennedy CC, Aksamit TR.

Mayo Clin Proc. 2006 Jan;81(1):85-8. No abstract available.

PMID:
16438483
42.

Introduction of a 14-hour work shift model for housestaff in the medical ICU.

Afessa B, Kennedy CC, Klarich KW, Aksamit TR, Kolars JC, Hubmayr RD.

Chest. 2005 Dec;128(6):3910-5.

PMID:
16354863
43.

Hot tub lung: presenting features and clinical course of 21 patients.

Hanak V, Kalra S, Aksamit TR, Hartman TE, Tazelaar HD, Ryu JH.

Respir Med. 2006 Apr;100(4):610-5. Epub 2005 Sep 27.

45.

Incidence of tuberculosis in Olmsted County, Minnesota, 1990-2001.

Jump SM, Sauver JL, Weaver AL, Bagniewski SM, Wilson JW, Huskins WC, Aksamit TR, Brutinel WM, Scalcini MC, Sia IG, Correa AG, McCoy K, Boyce TG.

Mayo Clin Proc. 2004 Sep;79(9):1119-23.

PMID:
15359465
46.

Hot tub lung: infection, inflammation, or both?

Aksamit TR.

Semin Respir Infect. 2003 Mar;18(1):33-9. Review.

PMID:
12652452
47.

Respiratory failure in tetanus: case report and review of a 25-year experience.

Bunch TJ, Thalji MK, Pellikka PA, Aksamit TR.

Chest. 2002 Oct;122(4):1488-92. Review.

PMID:
12377887
48.

Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease.

Aksamit TR.

Clin Chest Med. 2002 Sep;23(3):643-53. Review.

PMID:
12371000
49.

Diagnosis and treatment of allergic bronchopulmonary aspergillosis.

Vlahakis NE, Aksamit TR.

Mayo Clin Proc. 2001 Sep;76(9):930-8. Review.

PMID:
11560305
50.

Thromboembolism occurrence and diagnosis in the medical intensive care unit.

Aksamit TR.

Semin Thromb Hemost. 2001;27(1):47-57. Review.

PMID:
11288948

Supplemental Content

Loading ...
Support Center